

**Supplemental Table 1.** Prevalence, pharmacologic treatment, and control of hypertension among US non-pregnant women of reproductive age<sup>a</sup>

| Characteristic                                       | n   | % (95% CI)           |
|--|-----|----------------------|
| 2003 JNC 7 Guidelines                                |     |                      |
| Hypertension <sup>b</sup>                            | 483 | 9.0 (8.1, 9.9)       |
| Eligible for pharmacologic treatment <sup>c</sup>    | 483 | 100.0 (100.0, 100.0) |
| Current use of BP-lowering medication <sup>d</sup>   | 299 | 64.8 (60.1, 69.5)    |
| BP control <sup>e</sup>                              | 201 | 47.1 (42.4, 51.9)    |
| BP control among those using medication <sup>e</sup> | 201 | 72.7 (67.4, 78.1)    |
| 2017 ACC/AHA Guidelines                              |     |                      |
| Hypertension <sup>f</sup>                            | 961 | 19.3 (17.7, 20.9)    |
| Eligible for pharmacologic treatment <sup>g</sup>    | 566 | 54.5 (50.3, 58.7)    |
| Current use of BP-lowering medication <sup>h</sup>   | 299 | 55.5 (51.5, 59.9)    |
| BP control <sup>i</sup>                              | 146 | 16.1 (13.4, 18.8)    |
| BP control among those using medication <sup>i</sup> | 146 | 53.1 (46.4, 59.7)    |

Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; BP, blood pressure;

JNC 7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

- a) Data are from the National Health and Nutrition Examination Survey, 2011–March 2020, women aged 20–44 years (n=4,590). Ns are unweighted. Values are % (95% CI). Prevalence estimates are weighted and account for complex design.
- b) Hypertension defined as systolic BP  $\geq$ 140 mmHg or diastolic BP  $\geq$ 90 mmHg or self-reported current use of BP-lowering medication (JNC 7 2003).
- c) Eligibility for guideline-recommended pharmacologic treatment defined as self-reported current use of BP-lowering medication, systolic BP  $\geq$ 130 mmHg or diastolic BP  $\geq$ 80 mmHg among those with diabetes or chronic kidney disease, and systolic BP  $\geq$ 140 mmHg or diastolic BP  $\geq$ 90 mmHg among all other women

(JNC 7 2003). According to the JNC 7 guidance, all women with hypertension were eligible for guideline-recommended pharmacologic treatment.

- d) Among those with hypertension who were eligible for guideline-recommended pharmacologic treatment per 2003 JNC 7 ( $n=483$ ).
- e) Blood pressure control defined as systolic BP  $<130$  and diastolic BP  $<80$  mmHg among those with hypertension and diabetes or chronic kidney disease and systolic BP  $<140$  mmHg and diastolic BP  $<90$  mmHg among all other women with hypertension per 2003 JNC 7.
- f) Hypertension defined as systolic BP  $\geq 130$  mmHg or diastolic BP  $\geq 80$  mmHg or self-reported current use of BP-lowering medication (AHA/ACC 2017).
- g) Eligibility for guideline-recommended pharmacologic treatment defined as self-reported current use of BP-lowering medication, systolic BP  $\geq 130$  mmHg or diastolic BP  $\geq 80$  mmHg among women with diabetes, chronic kidney disease, or high risk of cardiovascular disease, or systolic BP  $\geq 140$  mmHg or diastolic BP  $\geq 90$  mmHg among all other women (AHA/ACC 2017).
- h) Among those with hypertension who were eligible for guideline-recommended pharmacologic treatment per 2017 ACC/AHA ( $n=528$ ).
- i) Blood pressure control defined as systolic BP  $<130$  mmHg and diastolic BP  $<80$  mmHg among those with hypertension per 2017 ACC/AHA.

**Supplemental Table 2.** Hypertension among US non-pregnant women of reproductive age 18-44y by race/Hispanic origin<sup>a</sup>, National Health and Nutrition Examination Survey, 2011–March 2020 (n=4,590)

| Characteristic  | <b>Hispanic<br/>(n=1,160)</b> | <b>NH Black<br/>(n=1,101)</b> | <b>NH White<br/>(n=1,491)</b> | <b>Another or multiple<br/>NH races<sup>b</sup><br/>(n=838)</b> | <b>P<sup>c</sup></b> |
|---|-------------------------------|-------------------------------|-------------------------------|---|----------------------|
| <b>2003 JNC 7<br/>Guidelines</b>                      |                               |                               |                               |   |                      |
| Hypertension <sup>d</sup>                             | 90<br>7.1 (5.8,8.4)           | 207<br>18.3<br>(16.0,20.7)    | 127<br>7.7 (6.4,9.1)          | 59<br>7.3 (4.9,9.6)   | <0.0001              |
| Eligible for pharmacologic treatment <sup>e</sup>     | 90<br>100.0<br>(100.0,100.0)  | 207<br>100.0<br>(100.0,100.0) | 127<br>100.0<br>(100.0,100.0) | 59<br>100.0<br>(100.0,100.0)                                    | -                    |
| Current use of BP-lowering medication <sup>f</sup>    | 55<br>59.1<br>(47.1,71.1)     | 123<br>58.4<br>(50.6,66.2)    | 92<br>72.4<br>(64.3,80.4)     | 29<br>52.3<br>(37.7,67.0)                                       | 0.01                 |
| BP control <sup>g</sup>                               | 45<br>46.0<br>(35.5,56.5)     | 71<br>36.1<br>(29.0,43.3)     | 67<br>54.9<br>(46.3,63.6)     | 18<br>39.8<br>(25.5,54.0)                                       | 0.004                |
| BP control among those using medications <sup>g</sup> | 45<br>77.9<br>(67.1,88.6)     | 71<br>61.9<br>(53.1,70.7)     | 67<br>75.9<br>(66.6,85.2)     | 18<br>76.0<br>(61.3,90.8)                                       | 0.09                 |
| <b>2017 ACC/AHA<br/>Guidelines</b>                    |                               |                               |                               |   |                      |
| Hypertension <sup>h</sup>                             | 175<br>14.0<br>(12.0,15.9)    | 351<br>30.9<br>(27.8,34.0)    | 290<br>18.5<br>(16.2,20.8)    | 145<br>18.2<br>(13.9,22.6)                                      | <0.0001              |

|  |     |                     |     |                     |     |                     |    |                                 |         |
|--|-----|---------------------|-----|---------------------|-----|---------------------|----|---------------------------------|---------|
| Eligible for pharmacologic treatment <sup>i</sup>    | 112 | 62.8<br>(55.4,70.3) | 231 | 65.5<br>(60.4,70.5) | 150 | 48.9<br>(43.2,54.6) | 73 | 49.7<br>(40.4,59.0)             | <0.0001 |
| Current use of BP-lowering medication <sup>j</sup>   | 55  | 47.9<br>(36.9,58.9) | 123 | 52.9<br>(45.7,60.2) | 92  | 61.8<br>(53.8,69.9) | 29 | 42.0<br>(28.1,55.8)             | 0.03    |
| BP control <sup>k</sup>                              | 36  | 18.6<br>(12.1,25.0) | 49  | 14.4<br>(11.2,17.5) | 53  | 18.0<br>(13.5,22.5) | 8  | 5.2 (1.1,9.3) <sup>l</sup>      | 0.007   |
| BP control among those using medication <sup>k</sup> | 36  | 61.7<br>(47.9,75.5) | 49  | 41.5<br>(33.9,49.1) | 53  | 59.6<br>(49.4,69.8) | 8  | 25.0<br>(3.9,46.1) <sup>l</sup> | 0.002   |

Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; BP, blood pressure; NH, non-Hispanic.

- a) Data are from the National Health and Nutrition Examination Survey, 2011–March 2020. Ns are unweighted. Values are % (95% CI). Prevalence estimates are weighted and account for complex design.
- b) Another or multiple non-Hispanic races includes non-Hispanic Asian, Native Hawaiian, Pacific Islander, American Indian, Alaskan Native, and people identifying with more than one race.
- c) *P* values calculated for Rao-Scott chi-square tests.
- d) Hypertension defined as systolic BP  $\geq 140$  mmHg or diastolic BP  $\geq 90$  mmHg or self-reported current use of BP-lowering medication (JNC 7 2003).
- e) Eligibility for guideline-recommended pharmacologic treatment defined as self-reported current use of BP-lowering medication, systolic BP  $\geq 130$  mmHg or diastolic BP  $\geq 80$  mmHg among those with diabetes or chronic kidney disease, and systolic BP  $\geq 140$  mmHg or diastolic BP  $\geq 90$  mmHg among all other women (JNC 7 2003). According to the JNC 7 guidance, all women with hypertension were eligible for guideline-recommended pharmacological treatment.
- f) Among those with hypertension who were eligible for guideline-recommended pharmacologic treatment per 2003 JNC 7.

- g) Blood pressure control defined as systolic BP <130 and diastolic BP <80 mmHg among those with hypertension and diabetes or chronic kidney disease and systolic BP <140 mmHg and diastolic BP <90 mmHg among all other women with hypertension per 2003 JNC 7.
- h) Hypertension defined as systolic BP  $\geq$ 130 mmHg or diastolic BP  $\geq$ 80 mmHg or self-reported current use of BP-lowering medication (AHA/ACC 2017).
- i) Eligibility for guideline-recommended pharmacologic treatment defined as self-reported current use of BP-lowering medication, systolic BP  $\geq$ 130 mmHg or diastolic BP  $\geq$ 80 mmHg among women with diabetes, chronic kidney disease, or high risk of cardiovascular disease, or systolic BP  $\geq$ 140 mmHg or diastolic BP  $\geq$ 90 mmHg among all other women (AHA/ACC 2017).
- j) Among those with hypertension who were eligible for guideline-recommended pharmacologic treatment per 2017 ACC/AHA.
- k) Blood pressure control defined as systolic BP <130 mmHg and diastolic BP <80 mmHg among those with hypertension per 2017 ACC/AHA.
- l) Interpret with caution. Estimate does not meet National Center for Health Statistics (NCHS) guidelines for reportability due to small denominator n.